[
  {
    "ts": null,
    "headline": "Danaher (NYSE:DHR) Partners With AstraZeneca To Advance Precision Medicine Diagnostics",
    "summary": "Danaher (NYSE:DHR) recently announced a collaboration with AstraZeneca to develop innovative diagnostic tools, possibly adding momentum to its 1.59% share price increase over the past week. However, this uptick aligns with the broader market gain of 1.2%, suggesting the partnership likely provided additional support rather than being a sole driver. Broader market sentiment was influenced by global trade developments and economic data indicating moderated inflation. Despite Danaher's ongoing...",
    "url": "https://finnhub.io/api/news?id=5f88994327fd757788be9586000dac4fa05186e201f1078d07e30049e75df9a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748625601,
      "headline": "Danaher (NYSE:DHR) Partners With AstraZeneca To Advance Precision Medicine Diagnostics",
      "id": 134905828,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "Danaher (NYSE:DHR) recently announced a collaboration with AstraZeneca to develop innovative diagnostic tools, possibly adding momentum to its 1.59% share price increase over the past week. However, this uptick aligns with the broader market gain of 1.2%, suggesting the partnership likely provided additional support rather than being a sole driver. Broader market sentiment was influenced by global trade developments and economic data indicating moderated inflation. Despite Danaher's ongoing...",
      "url": "https://finnhub.io/api/news?id=5f88994327fd757788be9586000dac4fa05186e201f1078d07e30049e75df9a8"
    }
  },
  {
    "ts": null,
    "headline": "Danaher Partners With AstraZeneca to Support Precision Medicine",
    "summary": "DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient selection and making advanced tests accessible worldwide.",
    "url": "https://finnhub.io/api/news?id=c82a29f9db08f10cbac57650832187f69d72db6a4f29abe2de4796d7b2031a8e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748620200,
      "headline": "Danaher Partners With AstraZeneca to Support Precision Medicine",
      "id": 134908589,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient selection and making advanced tests accessible worldwide.",
      "url": "https://finnhub.io/api/news?id=c82a29f9db08f10cbac57650832187f69d72db6a4f29abe2de4796d7b2031a8e"
    }
  },
  {
    "ts": null,
    "headline": "Danaher and AstraZeneca to develop diagnostic tools and tests",
    "summary": "The focus will initially be on creating computational and digital pathology products, as well as AI-assisted algorithms.",
    "url": "https://finnhub.io/api/news?id=7d77a892e1dd0313e3d16044da90ab71cdba70ae2182d0125eea0abaef0af211",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748614320,
      "headline": "Danaher and AstraZeneca to develop diagnostic tools and tests",
      "id": 134900904,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "The focus will initially be on creating computational and digital pathology products, as well as AI-assisted algorithms.",
      "url": "https://finnhub.io/api/news?id=7d77a892e1dd0313e3d16044da90ab71cdba70ae2182d0125eea0abaef0af211"
    }
  },
  {
    "ts": null,
    "headline": "Weitz Conservative Allocation Fund Q1 2025 Commentary",
    "summary": "The Conservative Allocation Fund's Institutional Class returned -0.24% for the first quarter compared to +1.95% for the Morningstar Moderately Conservative...",
    "url": "https://finnhub.io/api/news?id=7828030f79744634996391c2171de1d777fdb64c5714eade6b4437ffa5bb3490",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748599860,
      "headline": "Weitz Conservative Allocation Fund Q1 2025 Commentary",
      "id": 134900490,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192021620/image_2192021620.jpg?io=getty-c-w1536",
      "related": "DHR",
      "source": "SeekingAlpha",
      "summary": "The Conservative Allocation Fund's Institutional Class returned -0.24% for the first quarter compared to +1.95% for the Morningstar Moderately Conservative...",
      "url": "https://finnhub.io/api/news?id=7828030f79744634996391c2171de1d777fdb64c5714eade6b4437ffa5bb3490"
    }
  },
  {
    "ts": null,
    "headline": "Weitz Partners III Opportunity Fund Q1 2025 Commentary",
    "summary": "The Partners III Opportunity Fundâs Institutional Class returned -0.45% for the first quarter of 2025, comparing favorably to the Russell 3000 Indexâs return of -4.72%.",
    "url": "https://finnhub.io/api/news?id=da8cfa95344ccaca83ec538b7dc3a9dd78f7140f85d4404bab110e7e9f3fc588",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748599020,
      "headline": "Weitz Partners III Opportunity Fund Q1 2025 Commentary",
      "id": 134899752,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2043764026/image_2043764026.jpg?io=getty-c-w1536",
      "related": "DHR",
      "source": "SeekingAlpha",
      "summary": "The Partners III Opportunity Fundâs Institutional Class returned -0.45% for the first quarter of 2025, comparing favorably to the Russell 3000 Indexâs return of -4.72%.",
      "url": "https://finnhub.io/api/news?id=da8cfa95344ccaca83ec538b7dc3a9dd78f7140f85d4404bab110e7e9f3fc588"
    }
  },
  {
    "ts": null,
    "headline": "Weitz Multi Cap Equity Fund Q1 2025 Commentary",
    "summary": "The Multi Cap Equity Fundâs Institutional Class returned +0.81% for the quarter, comparing favorably to the Russell 3000 Indexâs loss of -4.72%.",
    "url": "https://finnhub.io/api/news?id=fed842ba6501204b15c506e5f69f4479c540a2c3fb665c5162e28a6dc92a1290",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748597040,
      "headline": "Weitz Multi Cap Equity Fund Q1 2025 Commentary",
      "id": 134896776,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2190009797/image_2190009797.jpg?io=getty-c-w1536",
      "related": "DHR",
      "source": "SeekingAlpha",
      "summary": "The Multi Cap Equity Fundâs Institutional Class returned +0.81% for the quarter, comparing favorably to the Russell 3000 Indexâs loss of -4.72%.",
      "url": "https://finnhub.io/api/news?id=fed842ba6501204b15c506e5f69f4479c540a2c3fb665c5162e28a6dc92a1290"
    }
  },
  {
    "ts": null,
    "headline": "Weitz Large Cap Equity Fund Q1 2025 Commentary",
    "summary": "Weitz Large Cap Equity Fund Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=20be1557f8321ddb46f87971d737ec67a2d13c4703af4bb7743a8cf49610d101",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748582820,
      "headline": "Weitz Large Cap Equity Fund Q1 2025 Commentary",
      "id": 134893038,
      "image": "",
      "related": "DHR",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=20be1557f8321ddb46f87971d737ec67a2d13c4703af4bb7743a8cf49610d101"
    }
  },
  {
    "ts": null,
    "headline": "Danaher partners with AstraZeneca to develop AI diagnostics",
    "summary": "Danaher Corp on Thursday said it has entered a partnership with AstraZeneca PLC to develop and commercialise tools and tests for precision medicine treatments, including artificial intelligence...",
    "url": "https://finnhub.io/api/news?id=75b08be688d791b0458392ed51e7d06889243252adff2eac901674849a894c9d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748581808,
      "headline": "Danaher partners with AstraZeneca to develop AI diagnostics",
      "id": 134892950,
      "image": "",
      "related": "DHR",
      "source": "Finnhub",
      "summary": "Danaher Corp on Thursday said it has entered a partnership with AstraZeneca PLC to develop and commercialise tools and tests for precision medicine treatments, including artificial intelligence...",
      "url": "https://finnhub.io/api/news?id=75b08be688d791b0458392ed51e7d06889243252adff2eac901674849a894c9d"
    }
  },
  {
    "ts": null,
    "headline": "Danaher Corporation (DHR) Launches Partnership with AstraZeneca PLC (AZN) to Scale Next-Gen Precision Medicine Tests",
    "summary": "Danaher Corporation (NYSE:DHR) and AstraZeneca PLC (NASDAQ:AZN) have announced a major partnership to accelerate the development and commercialization of advanced diagnostic tools aimed at expanding precision medicine. Leveraging DHR’s newly launched Centers for Enabling Precision Medicine, the collaboration will focus on creating AI-powered diagnostics to help clinicians better identify which patients are most likely to […]",
    "url": "https://finnhub.io/api/news?id=6edd66f16f960ecd4af7a81898035b60aaffae7f1b6b0dd0fa6ff67da3d5d16c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748574712,
      "headline": "Danaher Corporation (DHR) Launches Partnership with AstraZeneca PLC (AZN) to Scale Next-Gen Precision Medicine Tests",
      "id": 134894640,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "Danaher Corporation (NYSE:DHR) and AstraZeneca PLC (NASDAQ:AZN) have announced a major partnership to accelerate the development and commercialization of advanced diagnostic tools aimed at expanding precision medicine. Leveraging DHR’s newly launched Centers for Enabling Precision Medicine, the collaboration will focus on creating AI-powered diagnostics to help clinicians better identify which patients are most likely to […]",
      "url": "https://finnhub.io/api/news?id=6edd66f16f960ecd4af7a81898035b60aaffae7f1b6b0dd0fa6ff67da3d5d16c"
    }
  },
  {
    "ts": null,
    "headline": "Madison Large Cap Fund Q1 2025 Investment Strategy Letter",
    "summary": "Madison Large Cap Fund Q1 2025 Investment Strategy Letter",
    "url": "https://finnhub.io/api/news?id=90803472a4a5218d30fc3ab6b6a4c625701f62823a12946aac98aa6d4f142df0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748570040,
      "headline": "Madison Large Cap Fund Q1 2025 Investment Strategy Letter",
      "id": 134885332,
      "image": "",
      "related": "DHR",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=90803472a4a5218d30fc3ab6b6a4c625701f62823a12946aac98aa6d4f142df0"
    }
  }
]